Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00301834 · OUTCOME

Cytomegalovirus (CMV) Viral Infection and Disease Symptoms

Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders · Source last updated 2017-09-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
Up to one year post-transplant

What was measured

polymerase chain reaction testing for presence of CMV weekly until at least day +100 then every 2 weeks until T-cell reconstitution as defined by cluster of differentiation 4 (CD4) \> 200 cells/mm3. Median time to T-cell reconstitution was 6 months.

Analysis population: 4 participants were incapable of producing Ab or CMV testing result was indeterminate

Groups in this outcome

CMV Seronegative Participants

"seronegativity" means no detected presence of anti-CMV IgG, indicating no past infection by the virus

CMV Seropositive Participants

"seropositivity" means the presence of anti-CMV IgG, indicating past infection by the virus

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
CMV Seronegative Participants14
CMV Seropositive Participants17

Reported measurements

Positive CMV Viral Load Assay
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
CMV Seronegative Participants1Not reportedNot reportedNot reportedNot reported
CMV Seropositive Participants12Not reportedNot reportedNot reportedNot reported
Symptomatic CMV disease
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
CMV Seronegative Participants0Not reportedNot reportedNot reportedNot reported
CMV Seropositive Participants0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        12
    title
    Positive CMV Viral Load Assay
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
    title
    Symptomatic CMV disease
denoms
  1. counts
    1. group Id
      OG000
      value
      14
    2. group Id
      OG001
      value
      17
    units
    Participants
description
polymerase chain reaction testing for presence of CMV weekly until at least day +100 then every 2 weeks until T-cell reconstitution as defined by cluster of differentiation 4 (CD4) \> 200 cells/mm3. Median time to T-cell reconstitution was 6 months.
groups
  1. description
    "seronegativity" means no detected presence of anti-CMV IgG, indicating no past infection by the virus
    id
    OG000
    title
    CMV Seronegative Participants
  2. description
    "seropositivity" means the presence of anti-CMV IgG, indicating past infection by the virus
    id
    OG001
    title
    CMV Seropositive Participants
param Type
NUMBER
population Description
4 participants were incapable of producing Ab or CMV testing result was indeterminate
reporting Status
POSTED
time Frame
Up to one year post-transplant
title
Cytomegalovirus (CMV) Viral Infection and Disease Symptoms
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice